TTA-Q6 |
| Catalog No.GC30950 |
TTA-Q6은 T형 Ca2+ 채널의 선택적 길항제이며, 신경 과학 연구에 사용될 수 있다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 910484-28-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TTA-Q6은 T형 Ca2+ 채널의 선택적 길항제이며, 신경 과학 연구에 사용될 수 있다.
TTA-Q6은 양호한 전반적인 특성을 보여주고, T형 칼슘 채널 길항제에 반응하는 몇 가지 체내 실험에서 검사되었다. WAG/Rij 뇌전증 모델에서 3 mg/kg의 구강 투여 후 뇌전증 발작에 대한 강력한 억제 효과를 보였다. 대식기 전에 쥐에게 10 mg/kg의 TTA-Q6을 투여하면 투여 후 0.5-2시간 동안 활동적인 깨어있음을 추가로 억제한다[2]. TTA-Q6은 벤조아세테이트 유발한 정신운동 활동을 용량 종속적으로 감소시켰다[3].
References:
[1]: Schlegel KA, Yang ZQ, et,al.Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5147-52. doi: 10.1016/j.bmcl.2010.07.010. Epub 2010 Jul 8. PMID: 20673719.
[2]: Barrow JC, Rittle KE, et,al. Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists. ACS Med Chem Lett. 2010 Feb 1;1(2):75-9. doi: 10.1021/ml100004r. PMID: 24900180; PMCID: PMC4007971.
[3]: Uslaner JM, Smith SM, et,al. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology. 2012 Mar;62(3):1413-21. doi: 10.1016/j.neuropharm.2010.11.015. Epub 2010 Nov 24. PMID: 21110986.
| 동물 실험 [2]: | |
동물 모형 | WAG/Rij 뇌전증 모델 SD 쥐 |
제조 방법 | T형 통도 앙티아곤리스트의 수면 및 깨어있음에 대한 영향을 평가하기 위해, 쥐에서 전기피질도(ECoG) 및 육진도(EMG) 신호의 관측 기록이 진행되었습니다. 7일 교차 설계에서 비활성화 단계 30분 전에 매일 구강으로 차량 또는 TTA-Q6을 복용하였습니다. ECoG 및 EMG 신호는 각각의 수면 단계 또는 깨어 있는 시간에 대한 시간을 수집하고 평가되었습니다. |
제형 | 10 mg/kg TTA-Q6 ,7일 동안 매일 |
응용 분야 | 쥐의 수면 기전 직전에 10 mg/kg의 TTA-Q6을 투여한 것은 투여 후 0.5~2시간 동안 활동적인 깨어있음을 더욱 억제시켰습니다. |
참고문헌: [1]. Barrow JC, Rittle KE, et,al. Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists. ACS Med Chem Lett. 2010 Feb 1;1(2):75-9. doi: 10.1021/ml100004r. PMID: 24900180; PMCID: PMC4007971. | |
| Cas No. | 910484-28-5 | SDF | |
| Canonical SMILES | N#CC1=CC=C([C@]2(C3CC3)N(CC(F)(F)F)C(NC4=C2C=C(Cl)C=C4)=O)C=C1 | ||
| Formula | C20H15ClF3N3O | M.Wt | 405.8 |
| Solubility | DMSO : 125 mg/mL (308.03 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4643 mL | 12.3213 mL | 24.6427 mL |
| 5 mM | 0.4929 mL | 2.4643 mL | 4.9285 mL |
| 10 mM | 0.2464 mL | 1.2321 mL | 2.4643 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *